Maze Therapeutics Inc (MAZE) FinancialsMAZEMaze Therapeutics Inc

Evaluating the bottom line, Maze Therapeutics, Inc. maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -372.94%, while the net margin is -344.68%. These profitability ratios, combined with a Return on Equity (ROE) of -37.35%, provide a clear picture of how effectively MAZE converts its operational activities into shareholder value.

In the context of the broader market, MAZE competes directly with industry leaders such as OCUL and GPCR. With a market capitalization of $1.80B, it holds a leading position in the sector. When comparing efficiency, MAZE's gross margin of 100.00% stands against OCUL's 85.08% and GPCR's N/A. Such benchmarking helps identify whether Maze Therapeutics, Inc. is trading at a premium or discount relative to its financial performance.

Maze Therapeutics has shown a significant revenue potential with a projected $20 million in Q1 2026, and a gross margin of 100% in the same quarter. However, it has been operating at a loss, with a net income of -24.2 million in Q1 2026.